We also showed that administration of SGLT2 inhibitors preserved the eGFR with a reduction in blood pressure, urinary protein excretion (uPE), and serum uric acid (sUA) levels and elevation in hemoglobin level in patients with type 2 diabetes and an eGFR of <60 mL/min/1.73 m2(4), (5). Here, SLC5A2 is linked to type 2 diabetes mellitus.